Acute Chest Syndrome (Adult)

1. Clinical Overview

Summary

Acute Chest Syndrome (ACS) is a life-threatening pulmonary complication of sickle cell disease (SCD), defined as a new pulmonary infiltrate on chest X-ray (CXR) involving at least one complete lung segment, accompanied by fever (> 38.5°C) and/or respiratory symptoms (chest pain, cough, wheezing, tachypnoea, or hypoxia). It is the leading cause of death in adults with SCD and the second most common reason for hospitalisation after vaso-occlusive crisis (VOC). [1,2]

The clinical course is often unpredictable, with many cases developing 48–72 hours into an admission for a painful VOC. The pathophysiology involves a "vicious cycle" where regional hypoxia leads to red cell sickling in the pulmonary microvasculature, causing vaso-occlusion, further hypoxia, and inflammatory lung injury. Management requires a multi-modal "STAR" approach: Supportive care, Transfusion (simple or exchange), Antibiotics (covering atypical organisms), and Respiratory support (incentive spirometry). [3,4]

Key Facts

• Triggers: The "big three" are infection (e.g., Mycoplasma, Chlamydia, viruses), fat embolism (from bone marrow necrosis during VOC), and hypoventilation (often secondary to thoracic rib infarcts or excessive opiate use). [5]
• Incidence: ACS affects approximately 50% of patients with HbSS at least once. It is more frequent in children but carries a much higher mortality in adults.
• Hypoxia Threshold: In SCD, a PaO2 less than 9.3 kPa (70 mmHg) or a drop of 10% from baseline is highly significant. Unlike COPD, the target SpO2 in ACS is ≥95%.
• The "2-Day" Rule: Up to 50% of ACS cases develop after admission for a painful crisis. This makes prophylactic incentive spirometry mandatory for all SCD admissions. [6]
• Mortality: Approximately 1–5% per episode in adults; however, repeated episodes lead to chronic sickle cell lung disease and pulmonary hypertension.

Clinical Pearls

The "Silent CXR" Pearl: In the first 24 hours, the CXR may be normal even if the patient is hypoxic. If an SCD patient has chest pain and hypoxia, treat for ACS even if the initial film is "clear"—the infiltrate often appears 24 hours later.

The "Opiate Balance" Pearl: Pain management is crucial, but excessive opiates cause hypoventilation, which triggers atelectasis and ACS. Use regional anaesthesia or lidocaine patches for rib pain to spare the respiratory drive.

The "Exchange" Pearl: Do not wait for a patient to be intubated before calling for exchange transfusion. If they are deteriorating on simple top-up or have multi-lobar involvement, urgent exchange is the definitive treatment.

---

2. Epidemiology & Risk Factors

Incidence & Distribution

• Genotype Risk: Highest in HbSS and HbSβ°-thalassaemia; lower but still significant in HbSC and HbSβ+-thalassaemia.
• Age Dynamics: Children have a higher incidence of ACS (typically triggered by infection), while adults have a lower incidence but higher severity and mortality (often triggered by fat embolism).
• Seasonality: Peaks during winter months, correlating with the prevalence of respiratory viral infections. [7]

Risk Factors for Development

The transition from a standard painful crisis to ACS is often mediated by the following: [8]

---

3. Pathophysiology

1. The Vicious Cycle of Sickling

The pulmonary circulation is uniquely susceptible to sickling because it is a low-pressure, low-oxygen system. When a trigger (infection/atelectasis) causes regional hypoxia, deoxygenated HbS polymerises, distorting the red cell. These rigid cells adhere to the vascular endothelium, causing microvascular vaso-occlusion.

2. The Inflammatory Cascade

Vaso-occlusion leads to ischaemia-reperfusion injury. This triggers the release of:

• Secretory Phospholipase A2 (sPLA2): A potent inflammatory marker. Elevated levels correlate with the onset of ACS and the severity of lung injury.
• Free Fatty Acids: Released during bone marrow fat embolism; these are directly toxic to the pulmonary endothelium, causing capillary leak and non-cardiogenic pulmonary oedema (ARDS-like picture). [9]

3. V/Q Mismatch and Shunting

Microvascular occlusion and alveolar collapse (atelectasis) lead to profound ventilation-perfusion mismatch. As the PaO2 drops, systemic sickling is promoted, which further compromises the pulmonary vasculature, creating a self-perpetuating cycle of lung destruction.

4. Role of Nitric Oxide (NO)

Chronic haemolysis in SCD releases free haemoglobin, which scavenges NO. The resulting NO deficiency leads to pulmonary vasoconstriction and platelet activation, further exacerbating the vaso-occlusive process in the lungs. [10]

---

4. Clinical Presentation

Symptom Evolution

1. Initial Phase: Often begins as a standard VOC (back, limb, or chest wall pain).
2. Transition: Development of fever (> 38.5°C), tachypnoea, and a dry cough.
3. Established ACS: Pleuritic chest pain, productive cough (sometimes with blood-tinged sputum), and increasing oxygen requirement.
4. Late Phase: Respiratory distress, accessory muscle use, and potentially altered mental status if cerebral sickling co-occurs.

Physical Signs

• Tachypnoea: Often the most sensitive early sign (RR > 20–25 bpm).
• Hypoxia: SpO2 less than 95% or a significant drop from the patient's steady-state.
• Auscultation: Bronchial breathing, crackles, or wheezing (especially in patients with underlying asthma).
• Chest Wall: Tenderness over ribs or sternum (suggests bone infarction which may be the trigger).

Severity Grading

---

5. Investigations

1. Laboratory Assessment

• FBC: Look for a rapid drop in Haemoglobin (often > 20 g/L from baseline) and a rise in WCC.
• Reticulocyte Count: Usually high (compensated haemolysis), but a sudden drop suggests aplastic crisis.
• sPLA2 (if available): A rising trend is highly predictive of impending ACS in patients admitted with pain.
• Group & Screen: Essential for urgent cross-matching (requires extended phenotype matching to prevent alloimmunisation).
• Microbiology: Blood cultures, sputum culture, and viral PCR (Influenza/COVID/RSV). Atypical serology (Mycoplasma/Chlamydia) is high yield. [11]

2. Blood Gas Analysis

• ABG: Mandatory in any patient with SpO2 less than 94% or distress.
• Assessment: Look for the A-a gradient and PaO2. A PaO2 less than 9.3 kPa (70 mmHg) is a trigger for aggressive intervention.

3. Imaging

• Chest X-ray: The diagnostic cornerstone. Look for new opacification, often in the lower lobes. Note that CXR changes lag behind clinical symptoms by 12–24 hours.
• CT Pulmonary Angiogram (CTPA): Reserved for cases where PE is suspected (e.g., localized pain, no infiltrate, but high D-dimer/hypoxia), though ACS is much more common than PE in this population.

---

6. Management: The STAR Algorithm

Management Flowchart (ASCII)

               [SUSPECTED ACUTE CHEST SYNDROME]
              (SCD + Fever/Resp Sx + New Infiltrate)
                          |
            +-------------v-------------+
            |    IMMEDIATE STABILIZATION  | (STAR Protocol)
            | S - Support (O2, Fluids)    |
            | T - Transfusion (Assess)    |
            | A - Antibiotics (Atypical)  |
            | R - Respiratory (Spirometry)|
            +-------------+-------------+
                          |
            +-------------v-------------+
            |     ASSESS SEVERITY       |
            +-------------+-------------+
             /            |            \
      [MILD]           [MODERATE]       [SEVERE]
   Single lobe       2 lobes/Hypoxic   Bilateral/PaO2less than 9
    SpO2 > 92%        Hb stable         Neuro symptoms
        |                 |                 |
 +------v------+   +------v------+   +------v------+
 | SIMPLE      |   | SIMPLE vs   |   | URGENT      |
 | TOP-UP      |   | EXCHANGE    |   | EXCHANGE    |
 | (Aim Hb 100)|   | TRANSFUSION |   | TRANSFUSION |
 +------+------+   +------+------+   +------+------+
        |                 |                 |
        +----------------->-----------------+
                          |
               [CONTINUOUS MONITORING]
               (Pulse Ox, RR, sPLA2)

1. The STAR Protocol

• S - Support:
  • Oxygen: Maintain SpO2 ≥95%. Use high-flow nasal oxygen (HFNO) if needed.
  • Fluids: Cautious hydration (e.g., 2.5–3 L/day). Avoid overhydration which precipitates pulmonary oedema.
  • Analgesia: Multi-modal. Paracetamol, NSAIDs (if renal function permits), and cautious opiates.
• T - Transfusion:
  • Simple Transfusion: If Hb less than 90 g/L and patient is stable. Warning: Do not exceed Hb 110 g/L to avoid hyperviscosity.
  • Exchange Transfusion: Indications: PaO2 less than 9 kPa, multi-lobar disease, neurological symptoms, or failure to improve on simple transfusion. Aim for HbS less than 30%. [12]
• A - Antibiotics:
  • Third-generation Cephalosporin (e.g., Ceftriaxone) PLUS a Macrolide (e.g., Clarithromycin/Azithromycin) to cover atypicals.
• R - Respiratory Support:
  • Incentive Spirometry: 10 breaths every 2 hours while awake. This is the single most effective intervention to prevent progression.

2. Critical Care Indications

• Need for NIV or mechanical ventilation.
• Rapidly progressive infiltrates (> 1 lobe in 24 hours).
• Concurrent multi-organ failure (renal/hepatic).

---

7. Complications

• Acute Respiratory Distress Syndrome (ARDS): Rapid progression to bilateral white-out; requires high-pressure ventilation.
• Chronic Sickle Lung Disease: Recurrent ACS leads to restrictive lung disease and honeycombing.
• Pulmonary Hypertension (PH): Occurs in ~10% of SCD adults; associated with very high mortality. [13]
• Cerebral Fat Embolism / Stroke: Neurological deficits appearing alongside respiratory distress.
• Transfusion-Related Acute Lung Injury (TRALI): Can mimic ACS, making diagnosis difficult after transfusion.

---

8. Evidence & Landmark Trials

1. Vichinsky et al. (NEJM 2000): The definitive prospective study of 671 ACS episodes. It identified that infection and fat embolism were the primary triggers and established the standard of care for atypical antibiotic coverage. [PMID: 10871999]
2. Bellet et al. (NEJM 1995): A landmark RCT demonstrating that incentive spirometry significantly reduces the incidence of pulmonary complications in SCD patients admitted with chest or back pain. [PMID: 7637747]
3. The STOP Trial (1998): While primarily about stroke prevention, it established the safety and efficacy of chronic transfusion and the target HbS level (less than 30%) that is now applied to ACS management. [PMID: 9647873]
4. National Institutes of Health (NIH) Guidelines (2014): Consolidated evidence-based recommendations for the management of ACS, emphasizing the "simple vs. exchange" transfusion criteria. [14]

---

9. Single Best Answer (SBA) Questions

Question 1

A 22-year-old male with HbSS is admitted with a vaso-occlusive crisis. On day 2, his SpO2 drops from 98% to 91% on room air. He has a new fever of 38.8°C and pleuritic chest pain. CXR shows a new right lower lobe infiltrate. What is the most appropriate first-line respiratory intervention?

• A) Start IV Furosemide
• B) Urgent CT Pulmonary Angiogram
• C) Incentive spirometry (10 breaths every 2 hours)
• D) Intubate and ventilate
• E) Start Salbutamol nebulizers
• Answer: C. Incentive spirometry is the most effective evidence-based intervention to prevent the progression of ACS by reversing atelectasis.

Question 2

In the management of Acute Chest Syndrome, what is the most important reason to include a macrolide (e.g., Azithromycin) in the antibiotic regimen?

• A) To provide cover for Staphylococcus aureus
• B) To treat potential Mycoplasma pneumoniae infection
• C) To take advantage of its anti-inflammatory properties
• D) To cover for Gram-negative organisms
• E) To prevent secondary fungal pneumonia
• Answer: B. Atypical organisms like Mycoplasma and Chlamydia are common triggers for ACS and are not covered by cephalosporins.

Question 3

A 30-year-old female with ACS has a baseline haemoglobin of 75 g/L. Her current Hb is 68 g/L. She is tachypnoeic and her PaO2 on ABG is 8.5 kPa (64 mmHg) on 15L O2. What is the most appropriate transfusion strategy?

• A) Simple top-up transfusion to Hb 120 g/L
• B) Simple top-up transfusion to Hb 100 g/L
• C) Urgent automated exchange transfusion
• D) Wait for 24 hours to reassess
• E) Intravenous iron infusion
• Answer: C. A PaO2 less than 9 kPa (67 mmHg) or severe respiratory distress are clear indications for urgent exchange transfusion to rapidly reduce the HbS% without increasing viscosity.

Question 4

What is the target SpO2 for an adult patient with sickle cell disease and Acute Chest Syndrome?

• A) 88–92%
• B) 90–94%
• C) ≥95%
• D) ≥98%
• E) Room air only
• Answer: C. Unlike COPD, SCD patients require a higher target (≥95%) to prevent further deoxygenation-induced sickling.

Question 5

Which laboratory marker has been shown to be highly predictive of the onset of Acute Chest Syndrome in patients admitted with a painful crisis?

• A) Serum Ferritin
• B) D-dimer
• C) Secretory Phospholipase A2 (sPLA2)
• D) C-Reactive Protein (CRP)
• E) Serum Creatinine
• Answer: C. sPLA2 levels rise significantly 24–48 hours before the clinical appearance of ACS.

Question 6

A patient with ACS is being managed on the ward. Which of the following should be avoided in their hydration strategy?

• A) Oral water intake
• B) 0.9% Normal Saline at 125 mL/hr
• C) 5% Dextrose-Saline at 250 mL/hr
• D) Maintenance fluids at 3 L/day
• E) Normal Saline at 83 mL/hr
• Answer: C. Aggressive hydration (e.g., 250 mL/hr or > 4-5 L/day) should be avoided as it increases the risk of pulmonary oedema, which can worsen ACS.

Question 7

Which of the following defines Acute Chest Syndrome?

• A) Chest pain and fever only
• B) A new pulmonary infiltrate on CXR with respiratory symptoms
• C) Positive blood cultures and chest pain
• D) HbS level > 50%
• E) A drop in Hb > 20 g/L
• Answer: B. The definition requires the radiological finding of a new infiltrate plus clinical signs (fever/respiratory symptoms).

Question 8

Why is it dangerous to perform a simple top-up transfusion to a haemoglobin level of 130 g/L in a patient with SCD?

• A) It causes iron overload
• B) It precipitates acute renal failure
• C) It leads to hyperviscosity and increased stroke risk
• D) It suppresses the bone marrow
• E) It causes a hemolytic reaction
• Answer: C. Sickled red cells are inherently more viscous; raising the total Hb too high (typically > 110 g/L) with normal cells significantly increases blood viscosity.

Question 9

A 25-year-old with ACS develops sudden left-sided weakness and a facial droop. What is the most likely cause?

• A) Migraine with aura
• B) Todd's paralysis
• C) Cerebral fat embolism or stroke
• D) Side effect of Morphine
• E) Bell's palsy
• Answer: C. ACS and stroke often co-occur in SCD due to the systemic nature of the sickling crisis.

Question 10

Which medication is proven to reduce the long-term frequency of Acute Chest Syndrome episodes?

• A) Aspirin
• B) Hydroxyurea (Hydroxycarbamide)
• C) Warfarin
• D) Prednisolone
• E) Folic Acid
• Answer: B. Hydroxyurea increases HbF levels, which inhibits HbS polymerisation and has been shown to reduce ACS episodes by ~50%.

---

12. Hemorheology: The Vicious Cycle of Ischemia

Why does ACS progress so rapidly?

A. The Vaso-Occlusive Feedback Loop

• Trigger: A simple pain crisis, fat embolism from the bone marrow, or a minor infection causes local hypoxia in the lungs.
• The Sickling Reaction: Low oxygen levels cause HbS to polymerize (form stiff chains), turning flexible red cells into rigid "sickles."
• The Logjam: These rigid cells get stuck in the small lung capillaries, further reducing oxygen delivery and causing more sickling. This "vicious cycle" can involve the entire lung in hours.

B. The Role of Fat Embolism

• During a bone pain crisis, the marrow can become necrotic and release fat droplets into the blood. These droplets travel to the lungs, causing inflammation and triggering the sickling cycle described above.

---

13. Molecular Diagnostics: Secretory Phospholipase A2 (sPLA2)

The quest for a "Warning Light" for ACS.

A. sPLA2: The Predictive Marker

• Mechanism: sPLA2 is an enzyme that causes massive lung inflammation.
• The Insight: Levels of sPLA2 often rise 24–48 hours BEFORE the chest X-ray shows any changes.
• Clinical Potential: In the future, measuring sPLA2 during a simple pain crisis could identify which patients are about to develop ACS, allowing for early intervention with transfusion to prevent the crisis entirely.

---

14. Advanced Therapeutics: Transfusion Strategy

When to swap blood instead of just adding it.

A. Simple Transfusion

• Goal: Increase oxygen-carrying capacity.
• Limitation: Does not reduce the percentage of sickle cells (HbS%) significantly and increases the risk of "Hyperviscosity" (blood becoming too thick).

B. Exchange Transfusion (Erythrocytapheresis)

• The Power Move: Using a machine to remove the patient's sickle blood and replace it with donor blood.
• Target: The goal is to reduce the HbS% to less than 30% immediately. This is mandatory for patients with a falling pO2, neurological symptoms, or those failing to improve with simple transfusion.

---

15. Future Trends: Anti-Adhesion Therapy

Targeting the "Stickiness" of sickle cells.

A. P-Selectin Inhibitors (Crizanlizumab)

• Sickle cells are not just rigid; they are "sticky." They stick to the walls of the blood vessels via a protein called P-selectin.
• The Breakthrough: New drugs like Crizanlizumab block this stickiness, preventing the "logjam" from forming in the first place.

B. Gene Therapy and CRISPR

• The ultimate "cure" under trial: Using gene editing to switch back on the production of Fetal Hemoglobin (HbF), which never sickles, effectively making the patient immune to ACS.

---

16. Patient Explanation

"Acute Chest Syndrome is a very serious complication of sickle cell disease where the blood flow in your lungs becomes blocked by 'sickled' blood cells. Think of it like a traffic jam in the tiny tunnels of your lungs. This jam prevents oxygen from getting into your body, which makes you feel short of breath and causes chest pain. It often follows a regular pain crisis. This is why we insist you use your 'breathing exercise' device every hour—it helps keep the 'tunnels' open. If the jam gets too bad, we have to do an 'exchange transfusion,' which is like draining out the old, jam-clogged oil from a car and replacing it with fresh, clean oil so the engine can run again."

---

17. Examination Focus: Viva & OSCE Points

The "Crisis" Viva

• The "Crisis-to-ACS" Transition: Explain that ACS typically occurs 2.5 days after admission for a vaso-occlusive crisis. Fat embolism from infarcted bone marrow is a key driver.
• Transfusion Thresholds: Be able to justify the choice between "Simple" (Hb less than 7g/dL) and "Exchange" (Severe hypoxia/organ failure) transfusion.
• The Microbiological Mystery: Mention that in up to 70% of cases, no infection is found, but Atypical cover (Macrolides) is always given to cover Mycoplasma and Chlamydia.

---

18. References

1. Vichinsky EP, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000. [PMID: 10871999]
2. Howard J, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol. 2015. [PMID: 26136294]
3. Gladwin MT, et al. The acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011. [PMID: 21330600]
4. Piel FB, et al. Sickle cell disease. N Engl J Med. 2017. [PMID: 28423290]
5. Styles LA, et al. Secretory phospholipase A2 predicts induced acute chest syndrome. Blood. 1996. [PMID: 8639801]

---

Last Updated: 2026-01-05 | MedVellum Editorial Team